Work

Translation and Development of Molecular Imaging Probes for Detecting Response of Breast Cancer to Trastuzumab

Year: 2017
Type: dissertation
Abstract: The human epidermal growth factor receptor 2 (HER2) is overexpressed in up to 20% of breast cancers (BC) and confers an aggressive phenotype and a poor prognosis. Trastuzumab (Herceptin®) is a humanized anti-HER2 monoclonal antibody approved for immunotherapy of HER2-positive BC, however, many eligible patients do not derive benefit and better predictors of response are needed. SPECT/CT imaging with 111In-labeled pertuzumab has previously been shown to sensitively detect trastuzumab-mediated HER2 downregulation as a marker of response to trastuzumab therapy in HER2-overexpressing mouse xenografts. To advance this agent to the clinic, a kit for the preparation of 111In-BzDTPA-pertuzumab injection was developed under good manufacturing practices and tested against and consistently met quality specifications, including labeling efficiency, purity, sterility and endotoxins. Biodistribution, pharmacokinetic and radiation dosimetry studies of 111In-labeled pertuzumab in non-tumour bearing mice revealed no abnormal uptake in organs, slow elimination from the blood (t½β=228.2 h), and a projected total body radiation absorbed dose of 0.05 mSv/MBq. In an acute toxicity study of normal mice administered 23-times the planned clinical radioactivity dose (scaled), blood analyses revealed only slight changes in hemoglobin and serum creatinine levels; no differences in body weight between control and radiotracer injected groups, and no histopathological abnormalities of tissues were noted. A Phase I clinical trial was approved by Health Canada and initiated. A PET probe, 64Cu-NOTA-pertuzumab F(ab')2 was constructed to similarly detect HER2 changes in response to trastuzumab and was expected to have a lower radiation absorbed dose due to the faster elimination of F(ab')2 fragments and shorter half-life of 64Cu. The total body radiation absorbed dose projected for 64Cu-NOTA-pertuzumab F(ab')2 in humans was 0.015 mSv/MBq, a 3.3-fold reduction compared to 111In-BzDTPA-pertuzumab. PET/CT showed specific accumulation of 64Cu-NOTA-pertuzumab F(ab')2 in SK-OV-3 xenografted mice. Image analysis of mice treated with trastuzumab showed 2-fold reduced uptake of radioactivity in BT-474 xenografts injected with 64Cu-NOTA-pertuzumab F(ab')2 after 1 week of trastuzumab normalized to baseline, and 1.9-fold increased uptake in SK-OV-3 xenografts after 3 weeks of trastuzumab, consistent with tumour response and resistance, respectively. These results demonstrate that radiolabeled pertuzumab-based imaging probes are able to detect response to trastuzumab therapy.
Language: English
Field: Medicine
Open Access status: green
OpenAlex ID: W2777004218
Cites: 143
Cited by:
Related to: 10